Cited by 263Pancreatic function and diabetesDiabetes Treatment and ManagementProbiotics and Fermented Foods

Engineered commensal bacteria reprogram intestinal cells into glucose-responsive insulin-secreting cells for the treatment of diabetes

Open access
Duan, Franklin F., Liu, Joy H., March, John C.·2015·Diabetes

Abstract

The inactive full-length form of GLP-1(1-37) stimulates conversion of both rat and human intestinal epithelial cells into insulin-secreting cells. We investigated whether oral administration of human commensal bacteria engineered to secrete GLP-1(1-37) could ameliorate hyperglycemia in a rat model of diabetes by reprogramming intestinal cells into glucose-responsive insulin-secreting cells. Diabetic rats were fed daily with human lactobacilli engineered to secrete GLP-1(1-37). Diabetic rats fed GLP-1-secreting bacteria showed significant increases in insulin levels and, additionally, were significantly more glucose tolerant than those fed the parent bacterial strain. These rats developed insulin-producing cells within the upper intestine in numbers sufficient to replace ∼25-33% of the insulin capacity of nondiabetic healthy rats. Intestinal tissues in rats with reprogrammed cells expressed MafA, PDX-1, and FoxA2. HNF-6 expression was observed only in crypt epithelia expressing insulin and not in epithelia located higher on the villous axis. Staining for other cell markers in rats treated with GLP-1(1-37)-secreting bacteria suggested that normal function was not inhibited by the close physical proximity of reprogrammed cells. These results provide evidence of the potential for a safe and effective nonabsorbed oral treatment for diabetes and support the concept of engineered commensal bacterial signaling to mediate enteric cell function in vivo.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2337/db14-0635

Cites

37 of 37 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Microbial manipulations and supplementation of microbial metabolites are being considered as emerging preventive and therapeutic medicines for numerous disorders including those with gut barrier dysfunction and dysbiosis.

    “Microbial manipulations and supplementation of microbial metabolites are being considered as emerging preventive and therapeutic medicines for numerous disorders185, 186, 187 including those with gut barrier dysfunction and dysbiosis.”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Duan, F. F., Liu, J. H., & March, J. C.
Affiliations
Cornell University (US)
Corresponding author
March, John C.
Venue
Diabetes
Published
2015-01-27
Volume
64
Issue
5
Pages
1794-1803
ISSN
  • 0012-1797 (ISSN-L)
  • 1939-327X
OpenAlex
W2110588630
Cited by
263
References
37
Citations by year
2026: 16 · 2025: 33 · 2024: 27 · 2023: 30 · 2022: 35 · 2021: 20 · 2020: 23 · 2019: 21 · 2018: 21 · 2017: 17 · 2016: 13 · 2015: 7
FWCI
19.49
Type
journal article
Language
en
Open access
Locations
  • Diabetes (publishedVersion)
  • Europe PMC (PubMed Central) (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • NIH Office of the Director (1DP20D007155-01)
  • The Hartwell Foundation
Topics
  • Health Sciences › Medicine › Surgery › Pancreatic function and diabetes
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Life Sciences › Agricultural and Biological Sciences › Food Science › Probiotics and Fermented Foods
Keywords
insulin-secreting cells, diabetes treatment, oral administration, lactobacilli, hyperglycemia, glucose tolerance, MafA, PDX1, FOXA2, HNF6, crypt epithelium
MeSH terms
Insulin Secretion, Animals, Cell Line, Diabetes Mellitus, Diabetes Mellitus, Experimental, Epithelial Cells, Female, Gene Expression Regulation, Genetic Engineering, Glucose, Humans, Insulin, Intestinal Mucosa, Lactobacillus, Rats, Glucagon-Like Peptide 1, Cellular Reprogramming

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review